HighTower Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $152K | Sell |
17,000
-61
| -0.4% | -$547 | ﹤0.01% | 3358 |
|
|
2025
Q1 | $128K | Sell |
17,061
-539
| -3% | -$4.04K | ﹤0.01% | 3285 |
|
|
2024
Q4 | $132K | Sell |
17,600
-1,459
| -8% | -$11K | ﹤0.01% | 3274 |
|
|
2024
Q3 | $146K | Sell |
19,059
-1,091
| -5% | -$8.36K | ﹤0.01% | 3205 |
|
|
2024
Q2 | $124K | Buy |
20,150
+2,000
| +11% | +$12.3K | ﹤0.01% | 3121 |
|
|
2024
Q1 | $92K | Hold |
18,150
| – | – | ﹤0.01% | 3133 |
|
|
2023
Q4 | $109K | Buy |
18,150
+201
| +1% | +$1.21K | ﹤0.01% | 3143 |
|
|
2023
Q3 | $126K | Sell |
17,949
-651
| -4% | -$4.57K | ﹤0.01% | 3022 |
|
|
2023
Q2 | $131K | Buy |
+18,600
| New | +$131K | ﹤0.01% | 2986 |
|
|
2021
Q1 | – | Sell |
-25,726
| Closed | -$191K | – | 2844 |
|
|
2020
Q4 | $191K | Buy |
+25,726
| New | +$191K | ﹤0.01% | 2175 |
|
|
2014
Q4 | – | Sell |
-13,000
| Closed | -$127K | – | 1589 |
|
|
2014
Q3 | $127K | Buy |
+13,000
| New | +$127K | ﹤0.01% | 1413 |
|